Pdi inhibitor lti6426 enhances panobinostat efficacy in preclinical models of multiple myeloma

HIGHLIGHTS

• who: Reeder M. Robinson from the Department of Cellular and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Ashley Ave, MSC509, Charleston, SC, USA have published the Article: PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma, in the Journal: (JOURNAL)
• what: The authors propose such a regimen by combining Pano with LTI6426 a first-in-class orally bioavailable (PDI) inhibitor. The authors show that LTI6426 dramatically enhances the anti-MM activity of Pano in vitro and in vivo using a proteasome inhibitor resistant mouse model of MM and a . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.